Early estimation of pandemic influenza
Antiviral and Vaccine Effectiveness (EAVE):
use of a unique community and laboratory
national data-linked cohort study

Colin R Simpson,¹* Nazir Lone,¹ Jim McMenamin,²
Rory Gunson,³ Chris Robertson,⁴ Lewis D Ritchie⁵
and Aziz Sheikh¹

¹Centre for Medical Informatics, The Usher Institute of Population Health Sciences
and Informatics, The University of Edinburgh, Edinburgh, UK
²Health Protection Scotland, Glasgow, UK
³West of Scotland Specialist Virology Centre, Glasgow, UK
⁴Department of Mathematics and Statistics, University of Strathclyde,
Glasgow, UK
⁵Centre of Academic Primary Care, University of Aberdeen, Aberdeen, UK

*Corresponding author

Declared competing interests of authors: none

Published October 2015
DOI: 10.3310/hta19790

Scientific summary

The EAVE study
Health Technology Assessment 2015; Vol. 19: No. 79
DOI: 10.3310/hta19790

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

During the 20th and 21st centuries, there have been four pandemics (global epidemics) of influenza (1918–19, 1957–8, 1968–9, 2009–10) producing very large numbers of clinical cases and a large numbers of deaths (with an estimated 20–40 million, 1 million, 1 million and 0.25 million deaths, respectively). This was owing to the population having little immunity to the novel influenza viruses involved (H1N1, H2N2 and H3N2). Immunisation programmes delivered in primary health-care settings have been shown to be acceptable (as evidenced by previous high uptake rates) and effective, and this will therefore be the mainstay of disease prevention in any new influenza pandemic.

After the introduction of any new pandemic influenza, as well as front-line health-care workers, any new vaccination will be targeted at those who are considered to be at increased risk of serious illness or death from influenza infection, for example (1) those with any underlying medical conditions (e.g. chronic renal disease, immunosuppression resulting from disease or treatment, chronic heart disease, chronic respiratory disease); (2) those who may lack herd immunity (cross-reactivity) from exposure to previous pandemics or vaccinations; and (3) novel risk groups that are uniquely at risk because of a tropism exhibited by the virus. These national vaccination strategies have been shown to represent a potentially important approach to reduce both influenza-related illness and death, hence the considerable investment in this approach in many parts of the world.

Objectives

Building on prior work, we aimed to enhance a previously used data linkage approach, which allowed the effectiveness of the 2009 H1N1 influenza pandemic vaccine to be determined. We wished to create a pandemic influenza reporting platform. We anticipate that the platform will allow rapid extraction and linkage of general practice clinical, prescribing and vaccination data from sentinel general practices to virology laboratory information [serology and real-time polymerase chain reaction (RT-PCR) test results].

The objective of the platform is that, once a new pandemic is under way, the following should be rapidly determined:

- the uptake and effectiveness of any new pandemic vaccine (if) available
- the analysis of any protective effect conferred by antiviral drugs
- the clinical attack rate of pandemic influenza in general practice,

and, with stored serological information, determine:

- the existence of any protective effect provided by previous exposure to, and vaccination from, A/H1N1 pandemic or seasonal influenza/identification of susceptible groups.

Methods

The setting for this project was 41 participating general practices based throughout Scotland. The pre-pandemic phase of this project aimed to: complete all ethical, privacy and governance approvals; set up and test the data extraction systems; and create a repository of serology samples from patients registered with practices. Secure general practice data extraction systems supported by Trusted Third Party Albasoft Ltd have been tested.
Data on vaccination and other patient characteristics from general practice can be linked using the NHS Scotland’s unique patient identifier – the Community Health Index number to the Scottish Morbidity Record catalogue, which has information on all inpatient hospitalisations and mortality within Scotland, virological RT-PCR data and serological information collected from patients with influenza-like illness (ILI) by general practices. The West of Scotland Specialist Virology Centre (WoSSVC) will store 2000 biochemistry samples from a subset of participating practices within NHS Lothian and Greater Glasgow and Clyde Health Board areas.

In the event of any new pandemic influenza data, statistical scripts have been created that can calculate odds and risk ratios (adjusted for age, sex and deprivation) for differences in proportions of vaccine uptake between different groups of patients and for investigating trends in vaccine uptake. For vaccine effectiveness using information from linked virological swab data, a logistic regression model will be fitted, adjusting for the effects of sex, age, socioeconomic status and being in an at-risk morbidity group. In addition, using the cohort method, the proportion of ILI, acute respiratory disease and other adverse outcomes, such as hospitalisation or death from influenza, between vaccinated and unvaccinated cases will be ascertained. These data will also be used to determine the clinical attack rate of pandemic influenza.

To determine the existence of any protective effect provided by previous exposure to, and vaccination from, A/H1N1 pandemic or seasonal influenza/identification of susceptible groups, serology samples are linked to general practice data (which provide patient information on patient vaccination status, demographics and comorbidities/pregnancy). They will then be tested (once a validated haemagglutination inhibition assay has been developed) prior to the introduction of any vaccination. A seropositive result will be determined using the universally accepted cut-off point of a 1:40 dilution for a panel of influenza strains. These tests will be undertaken by the WoSSVC in Glasgow. A binomial analysis and logistic regression will be used to determine differences in seropositivity rates owing to age, sex, comorbidity and vaccination status. Results will be expressed as the mean seropositivity rate with 95% confidence intervals.

**Conclusions**

A new sentinel system capable of rapidly determining the estimated incidence of pandemic influenza, and pandemic influenza vaccine and antiviral uptake and effectiveness in preventing influenza and influenza-related clinical outcomes, has been created. We have all of the required regulatory approvals to allow rapid activation of the sentinel systems in the event of a pandemic. Of the 41 practices expressing an interest in participating, 40 have completed all of the necessary paperwork to take part in the reporting platform. The data extraction tool has been installed in these practices. Data extraction and deterministic linkage systems have been tested. Four biochemistry laboratories have been recruited, and systems for serology collection and linkage of samples to general practice data have been put in place.

**Study registration**

This study is registered as ISRCTN55398410.

**Funding details**

This project was funded by the NIHR Health Technology Assessment programme.
Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 11/46/23. The contractual start date was in January 2013. The report detailing the set up phase and initial outcomes began editorial review in June 2015 and was accepted for publication in July 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and production house have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report. Should the study progress further, the full report will be published in the HTA journal.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2015. This work was produced by Simpson et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Editor-in-Chief of *Health Technology Assessment* and NIHR Journals Library

**Professor Tom Walley**  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

**Professor Ken Stein**  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

**Professor Andree Le May**  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

**Dr Martin Ashton-Key**  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

**Professor Matthias Beck**  Chair in Public Sector Management and Subject Leader (Management Group), Queen's University Management School, Queen's University Belfast, UK

**Professor Aileen Clarke**  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick, UK

**Dr Tessa Crilly**  Director, Crystal Blue Consulting Ltd, UK

**Dr Peter Davidson**  Director of NETSCC, HTA, UK

**Ms Tara Lamont**  Scientific Advisor, NETSCC, UK

**Professor Elaine McColl**  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

**Professor William McGuire**  Professor of Child Health, Hull York Medical School, University of York, UK

**Professor Geoffrey Meadows**  Professor of Health Sciences Research, Faculty of Education, University of Winchester, UK

**Professor John Norrie**  Health Services Research Unit, University of Aberdeen, UK

**Professor John Powell**  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

**Professor James Raftery**  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

**Dr Rob Riemsma**  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

**Professor Helen Roberts**  Professor of Child Health Research, UCL Institute of Child Health, UK

**Professor Helen Snooks**  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

**Professor Jim Thornton**  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

**Editorial contact:** nihredit@southampton.ac.uk